Dyne Therapeutics, Inc. (NASDAQ: DYN) announced its fourth‑quarter and full‑year 2025 financial results on March 2, 2026. The company reported a net loss of $446.2 million for the year, up from $317.4 million in 2024, and a quarterly loss of $112.0 million, reflecting continued investment in its lead programs.
Cash, cash equivalents and marketable securities stood at $1.1 billion as of December 31, 2025, giving Dyne a runway into the first quarter of 2028. Research and development expenses totaled $398.3 million for the year, while general and administrative costs were $69.9 million, underscoring the company’s focus on clinical development rather than revenue generation.
The release highlighted key program milestones: a planned U.S. Accelerated Approval submission for z‑rostudirsen (DYNE‑251) in DMD is on track for Q2 2026, with a potential launch in Q1 2027; positive topline data from the Phase 1/2 DELIVER trial were reported in December; and enrollment in the Phase 1/2 ACHIEVE trial for z‑basivarsen (DYNE‑101) in myotonic dystrophy type 1 is expected to complete in Q2 2026. These developments reinforce Dyne’s strategy to move its FORCE platform‑based therapies through regulatory pathways ahead of commercial launch.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.